NCT06033586Phase 3Active not recruiting

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Study sponsor: Protagonist Therapeutics, Inc. · PTGX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-04-01Estimated
Enrollment · participants46Actual
Source updated2025-08-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview